CA3186645A1 - Antiplatelet drugs and uses thereof - Google Patents
Antiplatelet drugs and uses thereofInfo
- Publication number
- CA3186645A1 CA3186645A1 CA3186645A CA3186645A CA3186645A1 CA 3186645 A1 CA3186645 A1 CA 3186645A1 CA 3186645 A CA3186645 A CA 3186645A CA 3186645 A CA3186645 A CA 3186645A CA 3186645 A1 CA3186645 A1 CA 3186645A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- acceptable salt
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/105513 | 2020-07-29 | ||
| CN2020105513 | 2020-07-29 | ||
| PCT/CN2021/108875 WO2022022559A1 (en) | 2020-07-29 | 2021-07-28 | Antiplatelet drugs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3186645A1 true CA3186645A1 (en) | 2022-02-03 |
Family
ID=80037185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3186645A Pending CA3186645A1 (en) | 2020-07-29 | 2021-07-28 | Antiplatelet drugs and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12410132B2 (https=) |
| EP (2) | EP4188935A4 (https=) |
| JP (1) | JP2023535815A (https=) |
| KR (2) | KR102906376B1 (https=) |
| CN (4) | CN119033782B (https=) |
| AR (1) | AR123078A1 (https=) |
| AU (1) | AU2021317436A1 (https=) |
| BR (1) | BR112023001595A2 (https=) |
| CA (1) | CA3186645A1 (https=) |
| ES (1) | ES3046366T3 (https=) |
| IL (1) | IL299979A (https=) |
| MX (1) | MX2023001232A (https=) |
| TW (1) | TW202214609A (https=) |
| WO (1) | WO2022022559A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202339745A (zh) * | 2022-01-28 | 2023-10-16 | 大陸商上海柯君醫藥科技有限公司 | 抗血小板藥物的藥物組合物及其用途 |
| CN116813532A (zh) * | 2023-06-29 | 2023-09-29 | 上海柯君医药科技有限公司 | 一种哌啶化合物的制备方法 |
| WO2025108307A1 (zh) * | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用 |
| WO2025108300A1 (zh) * | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用 |
| CN119019320B (zh) * | 2024-10-29 | 2025-03-11 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119176829B (zh) * | 2024-11-26 | 2025-04-15 | 上海柯君医药科技有限公司 | 一种哌啶环化合物的制备方法 |
| CN119192061B (zh) * | 2024-11-28 | 2025-05-13 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
| CN119371453A (zh) * | 2024-12-30 | 2025-01-28 | 上海柯君医药科技有限公司 | 一种抗血小板药物中间体的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ334389A (en) | 1996-08-28 | 2001-05-25 | Ube Industries | Cyclic amine derivatives |
| US20060019929A1 (en) * | 2004-07-07 | 2006-01-26 | Albert Friesen | Combination therapies employing platelet aggregation drugs |
| CN104379589A (zh) * | 2012-05-07 | 2015-02-25 | 塞利克斯比奥私人有限公司 | 抗血小板药剂的前药 |
| KR20150038369A (ko) * | 2012-08-03 | 2015-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제제로서의 디히드로피리돈 P1 |
| CN103626694A (zh) * | 2012-08-29 | 2014-03-12 | 中国药科大学 | 不饱和环胺衍生物、其制备方法及其医药用途 |
| NO2721243T3 (https=) * | 2014-10-01 | 2018-10-20 | ||
| CN106554303A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN106554368A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN119019320B (zh) * | 2024-10-29 | 2025-03-11 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119192061B (zh) * | 2024-11-28 | 2025-05-13 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
-
2021
- 2021-07-28 CN CN202410873004.4A patent/CN119033782B/zh active Active
- 2021-07-28 IL IL299979A patent/IL299979A/en unknown
- 2021-07-28 CN CN202411716601.2A patent/CN119552111B/zh active Active
- 2021-07-28 MX MX2023001232A patent/MX2023001232A/es unknown
- 2021-07-28 BR BR112023001595A patent/BR112023001595A2/pt unknown
- 2021-07-28 KR KR1020257016343A patent/KR102906376B1/ko active Active
- 2021-07-28 US US18/018,576 patent/US12410132B2/en active Active
- 2021-07-28 WO PCT/CN2021/108875 patent/WO2022022559A1/en not_active Ceased
- 2021-07-28 ES ES24156405T patent/ES3046366T3/es active Active
- 2021-07-28 EP EP21851193.9A patent/EP4188935A4/en active Pending
- 2021-07-28 CN CN202311275197.5A patent/CN117343000A/zh active Pending
- 2021-07-28 KR KR1020237007048A patent/KR20230047425A/ko active Pending
- 2021-07-28 CA CA3186645A patent/CA3186645A1/en active Pending
- 2021-07-28 CN CN202180058245.8A patent/CN116194459A/zh active Pending
- 2021-07-28 EP EP24156405.3A patent/EP4342532B1/en active Active
- 2021-07-28 AU AU2021317436A patent/AU2021317436A1/en active Pending
- 2021-07-28 JP JP2023506150A patent/JP2023535815A/ja active Pending
- 2021-07-29 AR ARP210102107A patent/AR123078A1/es unknown
- 2021-07-29 TW TW110127818A patent/TW202214609A/zh unknown
-
2025
- 2025-07-08 US US19/262,108 patent/US20250333382A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4188935A4 (en) | 2024-07-17 |
| EP4342532B1 (en) | 2025-09-03 |
| KR20230047425A (ko) | 2023-04-07 |
| US20240279178A1 (en) | 2024-08-22 |
| MX2023001232A (es) | 2023-05-15 |
| EP4342532A2 (en) | 2024-03-27 |
| CN116194459A (zh) | 2023-05-30 |
| EP4342532C0 (en) | 2025-09-03 |
| AU2021317436A1 (en) | 2023-02-23 |
| IL299979A (en) | 2023-03-01 |
| US12410132B2 (en) | 2025-09-09 |
| KR102906376B1 (ko) | 2025-12-30 |
| WO2022022559A1 (en) | 2022-02-03 |
| ES3046366T3 (en) | 2025-12-01 |
| CN117343000A (zh) | 2024-01-05 |
| EP4342532A3 (en) | 2024-07-17 |
| KR20250073569A (ko) | 2025-05-27 |
| JP2023535815A (ja) | 2023-08-21 |
| US20250333382A1 (en) | 2025-10-30 |
| CN119552111B (zh) | 2026-01-02 |
| TW202214609A (zh) | 2022-04-16 |
| CN119033782A (zh) | 2024-11-29 |
| CN119552111A (zh) | 2025-03-04 |
| BR112023001595A2 (pt) | 2023-04-04 |
| EP4188935A1 (en) | 2023-06-07 |
| CN119033782B (zh) | 2025-04-25 |
| AR123078A1 (es) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3186645A1 (en) | Antiplatelet drugs and uses thereof | |
| JP2022549171A (ja) | 縮合ピリドン化合物、ならびにその調製方法および使用 | |
| IE862805L (en) | Benzimidazole derivatives | |
| EP4470539A1 (en) | Pharmaceutical composition of antiplatelet drug, and use thereof | |
| PL93499B1 (https=) | ||
| CA2926830A1 (en) | Thiazolopyrimidinones as modulators of nmda receptor activity | |
| BR112020019708A2 (pt) | compostos como moduladores de sinalização de tlr2 | |
| KR20220054287A (ko) | 뉴로키닌-1 길항제 | |
| KR102797099B1 (ko) | 2-[(3r)-3-메틸모르폴린-4-일]-4-(1-메틸-1h-피라졸-5-일)-8-(1h-피라졸-5-일)-1,7-나프티리딘의 제조 방법 | |
| RU2841656C1 (ru) | Антитромбоцитарные лекарственные средства и их применение | |
| US11834413B2 (en) | Antiplatelet drugs and uses thereof | |
| EP3773577A1 (en) | Tricyclic ask1 inhibitors | |
| HK40117914B (zh) | 抗血小板药物和其用途 | |
| HK40117914A (zh) | 抗血小板药物和其用途 | |
| HK40090099A (zh) | 抗血小板药物和其用途 | |
| WO2021202284A1 (en) | Modulators of hemoglobin | |
| CS142991A3 (en) | Alpha-oxopyrrolo/2,3-b/indolacetic acids, their esters, amides and analogs, process for their preparation and their application as medicaments | |
| WO2023138621A1 (en) | Atr inhibitors and uses thereof | |
| OA21175A (en) | Inhibitors of APOL1 and methods of using same. | |
| EA048667B1 (ru) | Циклоалкилпиримидины как ингибиторы ферропортина | |
| JPS61167691A (ja) | スピロ‐ジオキソラン、‐ジチオランおよび‐オキソチオラン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241119 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250718 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250718 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250724 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250724 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250724 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250728 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251002 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251002 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251002 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251002 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251002 |